Pharma company bags new order worth USD 3,01,090 from a leading pharma player

Asston Pharmaceuticals Limited has bagged a new international order valued at USD 301,090 from a prominent pharmaceutical company. This purchase order is for the supply of various pharmaceutical products and is considered a significant win that reinforces Asston's standing in the industry. The company is committed to delivering high-quality manufacturing solutions, and this contract will be fulfilled on a delivery basis, helping to solidify its position in the global pharmaceutical market.

Earlier, the company secured an international purchase order from a pharma company in West Africa for the supply of various pharmaceutical products, valued at USD 279,000. This order is to be executed within a timeframe of 60 days, or approximately two months.

Advertisement:

30% OFF on all DSIJ Investor and Trader Services

About the Company

Established in 2019, Asston Pharmaceuticals Limited manufactures and exports pharmaceutical formulations and nutraceuticals under its "Asston" brand. Operating with a diversified model, the company engages in direct sales, contract manufacturing for third parties, and significant exports, primarily to African markets. Its USFDA-approved facility in Ambernath, Maharashtra, supports a broad product portfolio and boasts over 150 registered trademarks.

For the period ended March 31, 2025, Asston Pharmaceuticals reported a revenue from operations of Rs 25.04 crore and a net profit of Rs 4.33 crore. The company currently holds a market capitalisation of Rs 87 crore. Its shares exhibit a Price-to-Earnings (PE) ratio of 25x, aligning with the industry average, and demonstrate strong profitability metrics with a Return on Equity (ROE) of 68 per cent and a Return on Capital Employed (ROCE) of 50 per cent. The stock up by 13.5 per cent from its 52-week low of Rs 96 per share.

Disclaimer: The article is for informational purposes only and not investment advice.